The company said revenue for the fiscal first quarter ended January 31, 2024 rose 9% from a year earlier to $931.6 million. CooperVision revenue increased 7% to $621.5 million, and CooperSurgical revenue increased 12% to $310.1 million.

1. 01

   The company said revenue for the fiscal first quarter ended January 31, 2024 rose 9% from a year earlier to $931.6 million. CooperVision revenue increased 7% to $621.5 million, and CooperSurgical revenue increased 12% to $310.1 million.

2. 02

   The Cooper Companies said GAAP diluted earnings per share for fiscal Q1 were $0.41, down $0.02 (5%) from a year earlier, while non-GAAP diluted earnings per share rose $0.12 (18%) to $0.85. Per-share figures for all periods reflect the 4-for-1 stock split effected on February 16, 2024.

3. 03

   The company said operating cash flow for fiscal Q1 was $122.7 million, and capital expenditures were $118.1 million, resulting in free cash flow of $4.6 million. Net debt at quarter-end was $2.6 billion.

4. 04

   The company said it raised its fiscal 2024 full-year outlook. It presented total revenue of $3,847 to $3,897 million (organic growth of 7% to 8%) and non-GAAP diluted EPS of $3.50 to $3.58.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.